Want to see GALT full AI Analyst Report?

Galectin Therapeutics (GALT) Price & Analysis

682 Followers

GALT Stock Chart & Stats

$3.47

-$0.09(-2.59%)

At close: Jul 27 4:00 PM EDT

$3.47

-$0.09(-2.59%)

Day’s Range― - ―

52-Week Range$2.03 - $7.13

Previous Close$3.42

Volume305.15K

Average Volume (3M)982.04K

Market Cap

$360.03M

Enterprise Value$432.36

Total Cash (Recent Filing)$13.27M

Total Debt (Recent Filing)$137.70M

Price to Earnings (P/E)―

Beta0.41

Next Earnings

Nov 16, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding100,849,650

10 Day Avg. Volume678,820

30 Day Avg. Volume982,042

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)-2.11

Price to Sales (P/S)0.00

P/FCF Ratio-11.13

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$11.00

Price Target Upside217.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.37

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt ReductionThe conversion materially reduces debt obligations and interest burden, improving balance-sheet flexibility for clinical development. It also preserves an additional undrawn $10 million facility, although future funding needs remain significant.

Regulatory ProgressFDA alignment gives belapectin a defined Phase 3 framework and supports a potential traditional approval route based on one confirmatory study. This reduces regulatory uncertainty and strengthens the asset’s partnering and development prospects.

Improving Cash BurnAlthough cash generation remains negative, the reduction in operating and free-cash-flow losses indicates improved cost control compared with prior periods. Sustained discipline could extend available funding and support continued clinical execution.

Bears Say

No Commercial RevenueWith no commercial product revenue, Galectin lacks an internally generated funding base and remains dependent on financing, partnerships or asset monetization. Persistent EBIT and net losses leave the company exposed to development delays and capital scarcity.

Stressed Balance SheetDeeply negative equity and debt that remains high relative to assets leave a thin capital cushion despite the recent conversion. This structure can constrain strategic flexibility and preserve refinancing, restructuring and dilution risks.

Shareholder Dilution And ControlDebt relief came with substantial share issuance and greater control concentration by the chairman and major shareholder. This may limit minority-holder influence and create governance and future dilution concerns as funding requirements continue.

Galectin Therapeutics News

Buy Rating Reaffirmed on GALT as Belapectin Program De-Risked; $11 Price Target Maintained

Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on Galectin Therapeutics and keeping the price target...

8d ago

GALT

Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion

The latest update is out from Galectin Therapeutics ( ($GALT) ). On July 31, 2026, Galectin Therapeutics converted...

18d ago

GALT

Galectin Therapeutics reaches alignment with FDA on belapectin pathway

Galectin Therapeutics (GALT) announced feedback from its recent in person Type C meeting with the FDA, supporting the...

2M ago

GALT

Galectin Advances Belapectin to Phase 3 After FDA Alignment

An update from Galectin Therapeutics ( ($GALT) ) is now available. On June 23, 2026, Galectin Therapeutics reported...

2M ago

GALT

Galectin Therapeutics presents belapectin data at EASL 2026

Galectin Therapeutics (GALT) announced the oral and poster presentations of new analyses from its global NAVIGATE trial of...

3M ago

GALT

Galectin Therapeutics publishes NAVIGATE Phase 2b trial results

Galectin Therapeutics (GALT) announced the publication of results from its NAVIGATE Phase 2b clinical trial evaluating belapectin in...

3M ago

GALT

Galectin Therapeutics files $200M mixed securities shelf

16:13 EDT Galectin Therapeutics (GALT) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

5M ago

GALT

Galectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet

Galectin Therapeutics (GALT) (GALT) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street...

5M ago

GALT

Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board

Galectin Therapeutics ( ($GALT) ) has provided an announcement. On March 12, 2026, Galectin Therapeutics appointed internationally recognized...

5M ago

GALT

Galectin Therapeutics appoints Henry Brem to board of directors

Galectin Therapeutics (GALT) has appointed Henry Brem, M.D., as an independent director to its Board of Directors. Dr....

5M ago

GALT

Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating

Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Galectin Therapeutics, retaining the price target of...

5M ago

GALT

Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT

Galectin Therapeutics (GALT) ($GALT) announced an update on their ongoing clinical study. Galectin Therapeutics Inc. (GALT) has terminated...

6M ago

GALT

Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT

Galectin Therapeutics (GALT) ($GALT) announced an update on their ongoing clinical study. Galectin Therapeutics Inc. (GALT) has terminated...

6M ago

GALT

Galectin Therapeutics Approves Retention Bonuses for Key Executives

An update from Galectin Therapeutics ( ($GALT) ) is now available. On January 16, 2026, Galectin Therapeutics’ board...

7M ago

GALT

GALT FAQ

What was Galectin Therapeutics (GALT)’s price range in the past 12 months?

Galectin Therapeutics (GALT) lowest stock price was $2.02 and its highest was $7.13 in the past 12 months.

What is Galectin Therapeutics (GALT)’s market cap?

Galectin Therapeutics (GALT)’s market cap is $360.03M.

When is Galectin Therapeutics (GALT)’s upcoming earnings report date?

Galectin Therapeutics (GALT)’s upcoming earnings report date is Nov 16, 2026 which is in 86 days.

How were Galectin Therapeutics (GALT)’s earnings last quarter?

Galectin Therapeutics (GALT) released its earnings results on Aug 14, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.05.

Is Galectin Therapeutics (GALT) overvalued?

According to Wall Street analysts Galectin Therapeutics (GALT)’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Galectin Therapeutics (GALT) pay dividends?

Galectin Therapeutics (GALT) does not currently pay dividends.

What is Galectin Therapeutics (GALT)’s EPS estimate?

Galectin Therapeutics (GALT)’s EPS estimate is -0.05.

How many shares outstanding does Galectin Therapeutics (GALT) have?

Galectin Therapeutics (GALT) has 100,849,650 shares outstanding.

What happened to Galectin Therapeutics (GALT)’s price movement after its last earnings report?

Galectin Therapeutics (GALT) reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -2.55%.

Which hedge fund is a major shareholder of Galectin Therapeutics (GALT)?

Currently, no hedge funds are holding shares in GALT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Galectin Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-4.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Galectin Therapeutics (GALT)

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

Galectin Therapeutics (GALT) Earnings & Revenues

Historic Earnings Reports

GALT Stock 12 Month Forecast

Average Price Target

$11.00

▲(217.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","12":"$12","3.75":"$3.75","6.5":"$6.5","9.25":"$9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.97,3.5876923076923077,4.205384615384616,4.823076923076924,5.440769230769231,6.058461538461538,6.676153846153847,7.293846153846154,7.911538461538461,8.52923076923077,9.146923076923077,9.764615384615384,10.382307692307693,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.97,3.5876923076923077,4.205384615384616,4.823076923076924,5.440769230769231,6.058461538461538,6.676153846153847,7.293846153846154,7.911538461538461,8.52923076923077,9.146923076923077,9.764615384615384,10.382307692307693,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.97,3.5876923076923077,4.205384615384616,4.823076923076924,5.440769230769231,6.058461538461538,6.676153846153847,7.293846153846154,7.911538461538461,8.52923076923077,9.146923076923077,9.764615384615384,10.382307692307693,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.42,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.81,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.97,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >